# Polaryx Therapeutics Inc. (PLYX)

Source: https://www.quantisnow.com/company/PLYX
Generated: 2026-11-11T18:20:37.930Z

- Ticker: PLYX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0002075320

## Latest PLYX news and filings

- 2026-11-09 13:30 UTC [Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200](https://www.quantisnow.com/insight/polaryx-therapeutics-activates-first-clinical-trial-site-for-soteria-phase-6780502)
- 2026-09-11 23:59 UTC [SEC Form 8-K] [Polaryx Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/polaryx-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6713536)
- 2026-09-01 20:30 UTC [SEC Form 8-K] [Polaryx Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/polaryx-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6701579)
- 2026-09-01 12:30 UTC [Leadership Update] [Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer](https://www.quantisnow.com/insight/polaryx-therapeutics-appoints-dr-will-charlton-as-chief-medical-officer-6700711)
- 2026-08-25 12:30 UTC [Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial](https://www.quantisnow.com/insight/polaryx-therapeutics-advances-operational-readiness-for-soteria-phase-2-basket-6693684)
- 2026-08-13 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Polaryx Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-polaryx-therapeutics-inc-6680657)
- 2026-08-13 12:33 UTC [Analyst Coverage Initiated] [Raymond James initiated coverage on Polaryx Therapeutics with a new price target](https://www.quantisnow.com/insight/raymond-james-initiated-coverage-on-polaryx-therapeutics-with-a-new-6679557)
- 2026-07-28 21:01 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Polaryx Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-polaryx-therapeutics-inc-6652059)
- 2026-07-28 21:00 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Polaryx Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-polaryx-therapeutics-inc-6652048)
- 2026-07-24 20:30 UTC [SEC Form S-8] [SEC Form S-8 filed by Polaryx Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-polaryx-therapeutics-inc-6648445)
- 2026-07-21 20:30 UTC [SEC Form 8-K] [Polaryx Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/polaryx-therapeutics-inc-filed-sec-form-8-k-leadership-update-6644011)
- 2026-07-17 12:00 UTC [SEC Form 8-K] [Polaryx Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events](https://www.quantisnow.com/insight/polaryx-therapeutics-inc-filed-sec-form-8-k-shareholder-director-nominations-6640537)
- 2026-07-09 13:30 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Polaryx Therapeutics with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-polaryx-therapeutics-with-a-new-6632688)
- 2026-05-29 00:00 UTC [Insider Buy] [Chief Executive Officer Yang Alex Keun Mo bought $360,004 worth of shares (88,453 units at $4.07) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-yang-alex-keun-mo-bought-360004-worth-6578021)
- 2026-05-28 20:31 UTC [SEC Form 8-K] [Polaryx Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/polaryx-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6577499)
- 2026-05-28 12:30 UTC [Public Offering] [Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial](https://www.quantisnow.com/insight/polaryx-therapeutics-announces-closing-of-10-million-private-placement-equity-6576293)
- 2026-05-14 13:15 UTC [Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards](https://www.quantisnow.com/insight/polaryx-therapeutics-receives-ghp-magazines-healthcare-pharmaceuticals-awards-6552875)
- 2026-04-23 12:30 UTC [Conference Announcement] [Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference](https://www.quantisnow.com/insight/polaryx-therapeutics-to-participate-in-national-tay-sachs-allied-diseases-association-6511849)
- 2026-04-21 12:30 UTC [Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial](https://www.quantisnow.com/insight/polaryx-therapeutics-receives-us-fda-fast-track-designations-for-all-6507823)
- 2026-04-15 13:15 UTC [Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care](https://www.quantisnow.com/insight/polaryx-therapeutics-recognized-with-pinnacle-award-for-excellence-in-pediatric-6500791)
- 2026-04-01 12:30 UTC [Conference Announcement] [Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference](https://www.quantisnow.com/insight/polaryx-therapeutics-to-participate-in-the-25th-annual-needham-virtual-6480916)
- 2026-03-17 12:30 UTC [Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)](https://www.quantisnow.com/insight/polaryx-therapeutics-receives-fda-fast-track-designation-for-plx200-for-6451305)
- 2026-03-12 12:30 UTC [Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events](https://www.quantisnow.com/insight/polaryx-therapeutics-deepens-engagement-with-the-krabbe-disease-community-through-6443631)
- 2026-02-27 13:30 UTC [Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders](https://www.quantisnow.com/insight/polaryx-therapeutics-marks-rare-disease-day-reaffirming-commitment-to-patients-6418019)
- 2026-02-27 13:13 UTC [Analyst Coverage Initiated] [Maxim Group initiated coverage on Polaryx Therapeutics with a new price target](https://www.quantisnow.com/insight/maxim-group-initiated-coverage-on-polaryx-therapeutics-with-a-new-6417945)
- 2026-02-20 21:41 UTC [Insider Buy] [Chief Financial Officer Landis G. Michael bought $7,991 worth of shares (2,867 units at $2.79), increasing direct ownership by 1% to 228,225 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-landis-g-michael-bought-7991-worth-of-6405112)
- 2026-02-17 13:30 UTC [Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial](https://www.quantisnow.com/insight/polaryx-therapeutics-selects-contract-research-organization-for-soteria-phase-2-6394577)
- 2026-02-10 13:30 UTC [Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™](https://www.quantisnow.com/insight/polaryx-announces-key-pre-clinical-data-related-to-soteria-at-the-6383213)
- 2026-02-05 13:30 UTC [Leadership Update] [Polaryx Therapeutics Welcomes New Members of the Board of Directors](https://www.quantisnow.com/insight/polaryx-therapeutics-welcomes-new-members-of-the-board-of-directors-6376842)
- 2026-02-03 13:30 UTC [Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch](https://www.quantisnow.com/insight/polaryx-to-present-late-breaker-data-related-to-soteria-at-the-6371437)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PLYX
- Earnings history: https://www.quantisnow.com/earnings/PLYX
- Dividend history: https://www.quantisnow.com/dividends/PLYX
- Insider transactions: https://www.quantisnow.com/insiders/PLYX
- Options chain: https://www.quantisnow.com/options/PLYX
- SEC 8-K filings only: https://www.quantisnow.com/company/PLYX/8-k
- RSS and alerts for PLYX: https://www.quantisnow.com/docs/rss-feeds.md